Patents Assigned to RECHERCHE MEDICALE)
-
Publication number: 20240173424Abstract: The present invention relates to an antibody -drug conjugate comprising a monoclonal antibody or an antigen-binding fragment thereof wherein the monoclonal antibody or the antigen-binding fragment thereof binds to Nectin-4 and wherein the drug is a topoisomerase I inhibitor, particularly exatecan.Type: ApplicationFiled: March 31, 2022Publication date: May 30, 2024Applicants: EMERGENCE THERAPEUTICS AG, UNIVERSITE D’AIX-MARSEILLE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), INSTITUT JEAN PAOLI & IRENE CALMETTES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE – CNRSInventors: Jack ELANDS, Florence LHOSPPICE, Xavier PRÉVILLE, Daniel OLIVE, Marc LOPEZ
-
Patent number: 11993781Abstract: The present invention relates to a method for obtaining stable pseudotyped lentiviral particles including a heterologous gene of interest, comprising the following steps: a) transfecting at least one plasmid in appropriate cell lines, wherein said at least one plasmid comprises the gene of interest, the rev. gag and pol genes, and a sequence coding for an ERV syncytin, wherein the rev, gag and pol genes are retroviral genes; b) incubating the transfected cells obtained in a), so that they produce the stable pseudotyped lentiviral particles in the supernatant; and c) harvesting and concentrating the stable lentiviral particles obtained in b). The present invention also relates to a method to transduce immune cells using lentiviral vectors pseudotyped with an ERV syncytin glycoprotein. The method can be performed on non-stimulated blood cells or on cells stimulated briefly with IL7, and the cells can be expanded. The stable pseudotyped lentiviral particles obtained are particularly useful in gene therapy.Type: GrantFiled: April 21, 2017Date of Patent: May 28, 2024Assignees: Institut National de la Santé et de la Recherche MédicaleInventor: Anne Galy
-
Patent number: 11987631Abstract: The present invention relates to humanized antibodies that specifically bind to human BTN3A and their use in treating cancer and infectious disorders.Type: GrantFiled: July 31, 2019Date of Patent: May 21, 2024Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ AIX MARSEILLE, INSTITUT JEAN PAOLI & IRENE CALMETTE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRSInventors: Alemseged Truneh, Daniel Olive, Christine Pasero, Aude De Gassart
-
Patent number: 11986514Abstract: This invention relates to the treatment of macular edema. Macular edema is the main cause of vision loss during diabetic macular edema, wet AMD (Age Related Macular Degeneration), retinal vein occlusion and chronic intraocular inflammation. Currently, beyond photocoagulation by laser irradiation, two types of drugs are used, protein molecules that neutralize VEGF family members and glucocorticoids, with different mechanisms of action, but targeting one single symptom: macular edema. The inventors have now found that macular edema may be treated by increasing the oncotic pressure of the vitreous. According to the inventors' understanding, causing an increase in the oncotic pressure of the vitreous induces a liquid flow from the interstitial water accumulated in the retina tissue to the vitreous compartment, so as to reduce or stop macular edema.Type: GrantFiled: August 31, 2018Date of Patent: May 21, 2024Assignees: INSERM (INSTITUT NATIONAL DE LASANTE ET DE LA RECHERCHE MEDICALE), SORBONNE UNIVERSITE, UNIVERSITE DE PARIS, ASSISTANCE PUBLIQUE—HOPITAUX DE PARISInventors: Francine Behar-Cohen, Raphael Cohen, Rinath Levy-Boukris, Min Zhao
-
Publication number: 20240158797Abstract: An antisense oligonucleotides having the ability to decrease the expression level of the huntingtin protein in glioma cells, for their use in sensitizing the cells to an anti-cancer treatment.Type: ApplicationFiled: March 18, 2022Publication date: May 16, 2024Applicants: UNIVERSITÉ GRENOBLE ALPES, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM), CENTRE HOSPITALIER UNIVERSITAIRE DE GRENOBLEInventors: Sandrine HUMBERT, Fabienne AGASSE, Frédéric SAUDOU, Kassem RAYANE
-
Patent number: 11981695Abstract: Disclosed is a linoleic acid derivative of Formula (I) below including a hydrophobic part C17H31 linked to a polar head part “A”: wherein the polar head part A is selected from A1 to A4 below: or a pharmaceutically/food quality acceptable salt thereof.Type: GrantFiled: May 27, 2019Date of Patent: May 14, 2024Assignees: UNIVERSITÉ DE BOURGOGNE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)Inventors: Naim Khan, Sylvain Juge, Aziz Hichami, Jérôme Bayardon, Marie-Laure Louillat-Habermeyer, Baptiste Rugeri
-
Patent number: 11981886Abstract: An infusible three-dimensional network of crosslinked acrylic-type polymer fibers, where the diameter of the fibers is between 0.1 and 1.5 ?m, the size of the interstices between the fibers is between 0.1 and 50 ?m2 and the stiffness of the network includes an elastic modulus between 0.01 and 10,000 kPa.Type: GrantFiled: February 15, 2019Date of Patent: May 14, 2024Assignees: UNIVERSITE DE MONTPELLIER, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, ECOLE NATIONALE SUPERIEURE DE CHIMIE DE MONTPELLIERInventors: David Cornu, Norbert Bakalara, Emilie Marhuenda, Ali Saleh
-
Publication number: 20240150721Abstract: The invention relates to the use of a laminin (LN) as a matrix for hepatic differentiation. The invention also relates to a method for inducing hepatic differentiation comprising the steps of: (i) providing a population of human pluripotent cells, (ii) culturing the population on a support coated with a laminin in a endoderm induction medium to produce a population of human DE cells, (iii) culturing said population of human DE cells on a support coated with a laminin in a hepatic induction medium to produce a population of human hepatoblasts-like cells, and (iv) optionally culturing said population of human hepatoblasts-like cells on a support coated with a laminin in a hepatic maturation medium to produce a population of human hepatocyte-like cells. The invention further relates to a population of human hepatoblasts-like cells or human fetal hepatocyte-like cells obtained by the method of the invention.Type: ApplicationFiled: November 17, 2023Publication date: May 9, 2024Applicants: INSERM (Institut National de la Santé et de la Recherche Médicale), Université de NantesInventors: Tuan Huy Nguyen, Angélique Fourrier
-
Publication number: 20240132547Abstract: The present invention relates to a virus-derived particle comprising one or more Cas protein(s), as well as to kits and methods using the same for altering a target nucleic acid.Type: ApplicationFiled: April 2, 2023Publication date: April 25, 2024Applicants: Institut National De La Sante Et De La Recherche Medicale (INSERM), Centre National De La Recherche Scientifique (CNRS), Ecole Normale Superieure De Lyon, Universite Claude Bernard Lyon 1Inventors: Théophile OHLMANN, Philippe MANGEOT, Emiliano RICCI
-
Publication number: 20240130358Abstract: An organ perfusion and preservation system for use in preserving an organ from a donor, may include a fluid reservoir, a heat exchanger in fluid communication with the fluid reservoir and configured to selectively raise and lower a temperature of a perfusion fluid, an oxygenator configured to oxygenate the perfusion fluid, an inflow pump in fluid communication with the fluid reservoir and the oxygenator, a fluid inflow line configured to transport perfusion fluid from the oxygenator to the organ, a fluid outflow line configured to transport perfusion fluid away from the organ and back to the reservoir, an outflow pump in fluid communication with the fluid outflow line and the fluid reservoir, and a controller operatively connected to the inflow pump, the outflow pump, and the heat exchanger, wherein the controller is configured to select parameters to reversibly heat and reversibly cool the organ.Type: ApplicationFiled: January 3, 2024Publication date: April 25, 2024Applicants: SORIN GROUP ITALIA S.R.L., SORBONNE UNIVERSITE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, ASSISTANCE PUBLIQUE- HOPITAUX DE PARISInventors: John F. Migliazza, Sandra Spiritelli, Olivier Scatton, Eric Savier, Claire Goumard
-
Publication number: 20240131138Abstract: Chlamydiae are intracellular bacterial pathogens responsible for a variety of infections. The inventors produced an antibody that is directed against a surface antigen (i.e., CD40) of an antigen presenting cell (i.e., dendritic cell) wherein the heavy chain and/or light chain is conjugated to the MOMP VS4 domain of Chlamydia trachomatis for its use as vaccine.Type: ApplicationFiled: December 22, 2021Publication date: April 25, 2024Applicants: Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance Publique - Hopitaux de Paris (APHP), Baylor Research Institute, Universite Paris Est Creteil Val De MarneInventors: Yves LEVY, Sylvain CARDINAUD, Mireille CENTLIVRE, Lydie DIEUDONNE, Sandra ZURAWSKI, Gérard ZURAWSKI
-
Publication number: 20240131505Abstract: A magnetic locking device for a pipetting tool, the device having a plate that is able to be adapted to the pipetting tool, an accessory being intended to be fastened to a fastening end piece that is supported by the plate and/or intended to be supported by the pipetting tool. The device has at least one lock configured to switch from an active state to a passive state, and vice versa, such that, in the active state, the lock is able to block, in service, particles that are present in the accessory, and such that, in the passive state of the lock, the particles are free to move in the accessory.Type: ApplicationFiled: February 25, 2022Publication date: April 25, 2024Applicants: UNIVERSITE DE VERSAILLES-SAINT-QUENTIN-EN-YVELINES, ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE - I.N.S.E.R.M.Inventor: Martin ROTTMAN
-
Publication number: 20240124532Abstract: Chlamydiae are intracellular bacterial pathogens responsible for a variety of infections. The inventors have set up candidate vaccines against Chlamydia trachomatis. In particular, the inventors have identified specific epitopes to be included in vaccine candidates thanks to in silico analysis of the amino-acid sequence of these proteins to map predicted MHC-I and -II epitopes by online software (NetMHC-4.0 and NetMHCII-2.3) and peptide binding prediction software. B cell epitopes were also mapped using online software (BepiPred-2.0 and Discotope). Finally, the inventors have generated some specific CD40 or Langerin antibodies comprising one or more identified epitope(s) of the present invention and that are suitable for vaccine purposes. Therefore, the present invention relates to Chlamydia trachomatis (Ct) antigenic polypeptides and uses thereof for vaccine purposes.Type: ApplicationFiled: January 28, 2022Publication date: April 18, 2024Applicants: Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance Publique - Hopitaux de Paris, Universite Paris Est Creteil Val De Marne, Baylor Research InstituteInventors: Yves LEVY, Sandra ZURAWSKI, Gérard ZURAWSKI, Mireille CENTLIVRE, Lydie DIEUDONNE, Sylvain CARDINAUD
-
Publication number: 20240116876Abstract: The present invention provides SOCE inhibitors that are useful as therapeutic agents in a variety of applications. The present invention also relates to pharmaceutical compositions, products and kits comprising such SOCE inhibitors, and methods of using the SOCE inhibitors in the treatment of a variety of diseases.Type: ApplicationFiled: May 19, 2021Publication date: April 11, 2024Applicants: Institut National de la Santé et de la Recherche Médicale, Universite de Bretagne Occidentale, Ecole Nationale Superieure de Chimie de Rennes, Institut National des Sciences Appliquees de Rennes, Universite Nangui Abrogoua, Centre National de la Recherche Scientifique, Universite de Rennes 1Inventors: Jean Pierre Bazureau, Déliko Camille Dago, Lou Anna Voli, Olivier Mignen, Christophe Brigaudeau, Yves-Alain Berko
-
Patent number: 11951090Abstract: FGFR3-related chondrodysplasias represent a group of rare diseases. Among them, achondroplasia, a nonlethal form of chondrodysplasia, is the most common type of dwarfism. The mutation, which produce an increase of FGFR3 function, affects many tissues, most strikingly the cartilaginous growth plate and bone in the growing skeleton, leading to a variety of manifestations and complications. In attempt to find a new therapeutic approach for FGFR3-related chondrodysplasia, the inventors purified (?)-epicatechin from T. cacao and showed that (?)-epicatechin treatment significantly increases the length of the Fgfr3Y367C/+ femurs comparing to Fgfr3+/+ femurs and improves the whole growth plate cartilage. The present invention thus relates to the use of (?)-epicatechin for the treatment of FGFR3-related chondrodysplasias.Type: GrantFiled: January 23, 2019Date of Patent: April 9, 2024Assignees: INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, UNIVERSITÉ DE PARIS, FONDATION IMAGINE, ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS, UNIVERSIDAD DE GRANADAInventors: Laurence Legeai-Mallet, Antonio Segura Carretero, Maria De La Luz Cadiz Gurrea
-
Publication number: 20240109940Abstract: The present invention relates to a virus-derived particle comprising one or more Cas protein(s), as well as to kits and methods using the same for altering a target nucleic acid.Type: ApplicationFiled: November 22, 2023Publication date: April 4, 2024Applicants: Institut National De La Sante Et De La Recherche Medicale (INSERM), Centre National De La Recherche Scientifique (CNRS), Ecole Normale Superieure De Lyon, Universite Claude Bernard Lyon 1Inventors: Théophile OHLMANN, Philippe MANGEOT, Emiliano RICCI
-
Patent number: 11944445Abstract: A method for automatically detecting elements of interest in electrophysiological signals includes: delivering electrophysiological signals; producing a whitened time-frequency representation of the electrophysiological signals; setting a threshold; applying this threshold to the whitened time-frequency representation; and, in the whitened time-frequency representation, detecting local maxima that are higher than or equal to the applied threshold.Type: GrantFiled: February 28, 2017Date of Patent: April 2, 2024Assignees: UNIVERSITÉ D'AIX-MARSEILLE (AMU), INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, ASSISTANCE PUBLIQUE—HÔPITAUX DE MARSEILLE (AP-HM)Inventors: Nicolas Roehri, Christian George Benar, Fabrice Bartolomei
-
Patent number: 11944616Abstract: The present invention relates to compounds of formula (I): for use as peripheral NMDA receptor antagonists.Type: GrantFiled: May 26, 2022Date of Patent: April 2, 2024Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITÉ PARIS-SACLAY, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS (APHP), HOPITAL MARIE LANNELONGUEInventors: Sylvia Cohen-Kaminsky, Marc Humbert, Sebastien Dumas, Gilles Bru-Mercier, Samir Messaoudi, Jean-Daniel Brion, Mouad Alami, Gilles Galvani
-
Patent number: 11945871Abstract: The present invention relates to humanized antibodies that specifically bind to human BTN3A and their use in treating cancer and infectious disorders.Type: GrantFiled: June 1, 2023Date of Patent: April 2, 2024Assignees: IMCHECK THERAPEUTICS SAS, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE AIX MARSEILLE, INSTITUT JEAN PAOLI & IRENE CALMETTE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRSInventors: Alemseged Truneh, Daniel Olive, Christine Pasero, Aude De Gassart
-
Publication number: 20240101616Abstract: A chimeric antigen receptor including: a binding domain, the full DAP 10 protein, the full DAP 12 protein, or a functional variant thereof, and a hook binding domain. Also, a vector system comprising one or more vector including: a nucleic acid comprising a nucleic acid sequence encoding a chimeric antigen receptor and optionally a nucleic acid encoding a hook fusion protein, preferably having a streptavidin core; wherein the nucleic acids are located on the same or on different vectors. Further, a lentiviral vector particles system, host cell and kit including the nucleic acids or vector system, and their use as a medicament, notably for immunotherapy.Type: ApplicationFiled: November 21, 2023Publication date: March 28, 2024Applicants: INSTITUT CURIE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)Inventors: Franck Perez, Zelia Gouveia, Sebastian Amigorena, Gaelle Boncompain